Epigral Plans ₹600 Crore Dahej Plant Expansion As Q1 Net Profit Drops To 1B Rupees

Market snapshot: Epigral Limited has announced a major strategic expansion in Dahej, Gujarat, involving an estimated ₹600 crore investment to build an Epoxy Resin facility and a Multi-Purpose Plant. Alongside this capital expenditure news, the company declared its financial results for the quarter ended June 30, 2026, where consolidated net profit dropped by 37.9% year-on-year to ₹99.74 crore due to a high tax base effect from the previous year, while consolidated revenue from operations grew 16.3% to ₹705.36 crore.

Data Snapshot

• Epigral achieved a consolidated revenue from operations of ₹705.36 crore for the quarter ended June 30, 2026, marking a 16.3% growth from ₹606.54 crore in the year-ago period.
• Consolidated net profit stood at ₹99.74 crore, reflecting a 37.9% year-on-year decline from ₹160.69 crore due to tax base effects.
• The company's standalone profit before tax grew 24.8% year-on-year to ₹133.18 crore compared to ₹106.73 crore in the corresponding period.
• The proposed expansion facility in Dahej requires an estimated investment of ₹600 crore, aiming to add 1,25,000 TPA of Epoxy Resin & Formulations capacity by H2 FY2028.

What's Changed

• Standalone profit before tax increased by 24.8% YoY to ₹133.18 crore, proving strong operational underlying momentum.
• Finance costs decreased significantly by 69.1% YoY to ₹7.22 crore, showing massive debt cost relief (derived: ₹7.22 crore vs ₹23.37 crore).
• Epigral is transitioning its product mix by entering the specialty Epoxy Resin value chain, expanding its integrated complex in Dahej, Gujarat.
• The total tax expense surged to ₹34.00 crore in the current quarter, compared to a net tax benefit of ₹53.68 crore in the prior-year period.

Key Takeaways

• The 37.9% net profit drop is an optical artifact of tax adjustments; operating pre-tax profitability actually climbed 25%.
• Robust core sales growth is driven by better volumes and price realizations in the chlor-alkali and specialty segments.
• The ₹600 crore capex program enhances downstream chemical integration, capturing import-substitution markets for Epoxy Resins.
• Excellent cost control has significantly reduced interest expenses, lowering financing hurdles for future expansions.

SAHI Perspective

A superficial view of Epigral's results would highlight the 38% net profit decline. However, smart money will track the 25% standalone pre-tax profit increase. Operationally, Epigral is in a strong position. By leveraging its existing Chloro-Alkali infrastructure to venture downstream into high-value Epoxy Resins, the company is shielding its margins from primary chemical price cycles. The ₹600 crore project, financed via debt and internal accruals, is supported by a stable capital structure and its recent rating reaffirmation of AA by CRISIL, making it a highly prudent growth driver.

Market Implications

Entering the Epoxy Resin and formulation markets is a high-margin move for Epigral. Currently, India is highly dependent on imports for Epoxy Resins, and adding 1,25,000 TPA capacity helps substitute these imports. This expansion is likely to lead to long-term valuation re-rating as specialty chemical volumes increase relative to basic commodity chemicals. In the short term, any negative market reaction to the headline net profit decline could present a strong buying opportunity given the stellar operating pre-tax growth.

Trading Signals

Market Bias: Bullish

The underlying 25% standalone PBT growth to ₹133.18 crore and the major strategic ₹600 crore specialty chemicals capex heavily outweigh the optics of a tax-driven PAT decline.

Overweight: Specialty Chemicals, Industrial Materials, Import Substitution

Underweight: Import-dependent chemical intermediaries

Trigger Factors:

• Absorption of Q1 tax base effect by the market
• Debt-equity financing finalization for the ₹600 crore expansion
• Updates on construction and pre-booking orders at the Dahej facility

Time Horizon: Medium-term (3-12 months)

Industry Context

The Indian specialty chemical space is experiencing a pivot toward deep integration. Epoxy resins are vital for automotive coatings, windmill blade manufacturing, electronics, and construction adhesives. By integrating forward from Caustic Soda and Chlorine into Epoxy Resins at Dahej, Epigral is maximizing its regional feedstock advantage and capturing a greater share of the domestic industrial value chain.

Key Risks to Watch

• Project implementation delays for the new Dahej facility, which is slated for H2 FY2028.
• Potential pricing pressure on raw material inputs if basic chemical commodities experience severe global volatility.
• Interest rate hikes affecting cost-of-capital on the debt component of the capex funding.

Recent Developments

On June 4, 2026, CRISIL Ratings reaffirmed its 'CRISIL AA/Stable/CRISIL A1+' ratings on Epigral's bank facilities, highlighting the company's strong capital structure and healthy debt protection metrics. In May 2026, Epigral posted its highest-ever quarterly revenue of ₹736 crore for Q4 FY26, which was up 17% year-on-year.

Closing Insight

Epigral's underlying financial strength is excellent, as evidenced by a solid 25% growth in pre-tax profits. This operating performance combined with a structural transition to specialty Epoxy Resins makes it a highly promising specialty chemical player to watch.

High Performance Trading with SAHI.